Version 1
: Received: 15 August 2023 / Approved: 16 August 2023 / Online: 16 August 2023 (07:09:24 CEST)
How to cite:
Horrany, N.; Nassar, B.; Lynn, M.; Zreik, M.; Hassan, M.; Blum, A. Effect of Pre-stroke Treatment of ACE Inhibitors/Angiotensin Receptor Blockers on Ischemic Stroke Severity and Functional Outcome. Preprints2023, 2023081173. https://doi.org/10.20944/preprints202308.1173.v1
Horrany, N.; Nassar, B.; Lynn, M.; Zreik, M.; Hassan, M.; Blum, A. Effect of Pre-stroke Treatment of ACE Inhibitors/Angiotensin Receptor Blockers on Ischemic Stroke Severity and Functional Outcome. Preprints 2023, 2023081173. https://doi.org/10.20944/preprints202308.1173.v1
Horrany, N.; Nassar, B.; Lynn, M.; Zreik, M.; Hassan, M.; Blum, A. Effect of Pre-stroke Treatment of ACE Inhibitors/Angiotensin Receptor Blockers on Ischemic Stroke Severity and Functional Outcome. Preprints2023, 2023081173. https://doi.org/10.20944/preprints202308.1173.v1
APA Style
Horrany, N., Nassar, B., Lynn, M., Zreik, M., Hassan, M., & Blum, A. (2023). Effect of Pre-stroke Treatment of ACE Inhibitors/Angiotensin Receptor Blockers on Ischemic Stroke Severity and Functional Outcome. Preprints. https://doi.org/10.20944/preprints202308.1173.v1
Chicago/Turabian Style
Horrany, N., Muhammad Hassan and Arnon Blum. 2023 "Effect of Pre-stroke Treatment of ACE Inhibitors/Angiotensin Receptor Blockers on Ischemic Stroke Severity and Functional Outcome" Preprints. https://doi.org/10.20944/preprints202308.1173.v1
Abstract
A growing number of clinical data suggests that the use of antiplatelets and/or statins pre-stroke are associated with reduced severity and better functional outcomes for ischemic stroke. Studies have shown that the long-term use of ACEI/ARB pre-stroke is beneficial in reducing severity at onset and improving functional outcomes. We aimed to compare stroke severity and early functional outcome between patients taking ACEI/ARB and those who were not, and to identify any additional effects to taking ACEI/ARB with antiplatelets, statins, or both.
In this retrospective case-control study, we assessed 218 patients who presented with ischemic stroke to the stroke unit in Padeh-Poriyah Hospital between 2019-2020. Of these patients, 119 took ACEI/ARB pre-stroke. A significantly higher percentage of ACEI/ARB-treated patients had a history of hypertension (HTN) and hyperlipidemia and were taking antiplatelets and/or statins, compared to the non-ACEI/ARB group. We observed that pre-stroke treatment with ACEI/ARB is associated with worsened stroke severity and reduced early functional outcomes.
No significant benefit to taking ACEI/ARB with antiplatelets and/or statins pre-stroke was observed. Due to the nature of our study, the data should be interpreted as suggestive. Thus, prospective studies of these medications on ischemic stroke severity and early outcomes are warranted.
Keywords
ACEI – Angiotensin converting enzyme inhibitor; HTN - Hypertension; mRS – Modified ranking scale; NIHSS – National institute of health stroke scale
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
